SLC5A2 and heart failure: In recent years, researchers have found that SGLT2-i originally used for the treatment of diabetes have potential effects in the treatment of heart failure, among which dapagliflozin not only meets the clinical hypoglycemic needs, but also has an obvious role in cardiovascular aspects.